Diabetes care最新文献

{"title":"About the Editor: Meghana Gadgil, MD, MPH-Preventative Nutrition Recommendations for South Asian Populations.","authors":"Benjamin Page","doi":"10.2337/dci25-0027","DOIUrl":"https://doi.org/10.2337/dci25-0027","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":"48 5","pages":"670"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"About the Artists: John B. Buse, MD, PhD, and Mary Beth Cassely, MSPH.","authors":"Benjamin Page","doi":"10.2337/dci25-0026","DOIUrl":"https://doi.org/10.2337/dci25-0026","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":"48 5","pages":"669"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease.","authors":"John W Ostrominski, Brian L Claggett, Zi Michael Miao, Gerasimos Filippatos, Akshay S Desai, Pardeep S Jhund, Alasdair Henderson, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Carolyn S P Lam, Michele Senni, Sanjiv J Shah, Adriaan A Voors, Faiez Zannad, Peter Rossing, Luis M Ruilope, Stefan D Anker, Bertram Pitt, Rajiv Agarwal, John J V McMurray, Scott D Solomon, Muthiah Vaduganathan","doi":"10.2337/dc24-1873","DOIUrl":"10.2337/dc24-1873","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in individuals with type 2 diabetes (T2D) and either chronic kidney disease (CKD) or heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF).</p><p><strong>Research design and methods: </strong>In this prespecified participant-level pooled analysis of all phase III clinical trials evaluating finerenone versus placebo conducted to date (FINE-HEART), the safety and efficacy of finerenone was evaluated among participants with a history of T2D. Treatment effects on the primary outcome of cardiovascular death and other secondary outcomes were evaluated according to baseline glycated hemoglobin (HbA1c) and glucose-lowering therapy (GLT) regimen using stratified Cox proportional hazards models.</p><p><strong>Results: </strong>Of 18,991 FINE-HEART participants, 15,365 (80.9%) had T2D and available HbA1c at baseline (mean age, 66 ± 10 years; 32% women; mean HbA1c, 7.6 ± 1.4%). The most common GLT regimens were insulin alone (n = 2,652), insulin and metformin (n = 2,005), metformin alone (n = 1,616), metformin and sulfonylurea (n = 1,039), and \"other\" (n = 8,117), including sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide 1 receptor agonist (GLP-1RA). Over a median follow-up of 2.9 years, treatment effects of finerenone versus placebo on cardiovascular death were consistent across baseline HbA1c (Pinteraction = 0.75) and GLT regimen (Pinteraction = 0.46). Finerenone consistently reduced the kidney composite outcome, HF hospitalization, major adverse cardiovascular events, and all-cause mortality, irrespective of baseline HbA1c and GLT regimen. Treatment effects of finerenone were also consistent across number of background GLTs and irrespective of concomitant treatment with a SGLT2i or GLP-1RA.</p><p><strong>Conclusions: </strong>Finerenone consistently reduced morbidity and mortality in individuals with T2D across a broad range of glycemia and glucose-lowering regimens.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"745-755"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143528096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Glucagon-Like Peptide 1 Analog as an Adjuvant Therapy in Generalized Lipodystrophy.","authors":"Yael Lebenthal, Sharon Halperin, Hagar Interator, Avivit Brener, Rebecca J Brown","doi":"10.2337/dc25-0272","DOIUrl":"10.2337/dc25-0272","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"e71-e73"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12034891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143660046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on Christiaens et al. Diabetes Overtreatment and Hypoglycemia in Older Patients With Type 2 Diabetes on Insulin Therapy: Insights From the HYPOAGE Cohort Study. Diabetes Care 2025;48:61-66.","authors":"Ching-Yang Cheng, Chien-Ning Huang, Yi-Sun Yang, Edy Kornelius","doi":"10.2337/dc25-0071","DOIUrl":"https://doi.org/10.2337/dc25-0071","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":"48 5","pages":"e77-e78"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Medical Identification for People Living With Type 1 Diabetes: Results From the BETTER Registry.","authors":"Virginie Messier, Anne-Sophie Brazeau, Maha Lebbar, Peter A Senior, Laure Alexandre-Heymann, Barbara Kelly, Caroline Grou, Rémi Rabasa-Lhoret","doi":"10.2337/dc25-0058","DOIUrl":"10.2337/dc25-0058","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"e68-e70"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Oral Semaglutide Versus Comparators on Multiple Cardiometabolic Risk Factor Control in Adults With Type 2 Diabetes.","authors":"Vanita R Aroda, Brian Malling, Juris J Meier, Morten T Abildlund, Pranav Kelkar, Tina Vilsbøll, Kamlesh Khunti","doi":"10.2337/dc24-2373","DOIUrl":"10.2337/dc24-2373","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"e65-e67"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12034892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Historical Redlining With Gestational Diabetes Mellitus: The Mediating Role of BMI and Area Deprivation Index.","authors":"Wajeeha Umer, Yi Sun, Anqi Jiao, Karen D Lincoln, Mengyi Li, Chantal C Avila, Vicki Y Chiu, Jeff M Slezak, David A Sacks, John Molitor, Tarik Benmarhnia, Jiu-Chiuan Chen, Darios Getahun, Jun Wu","doi":"10.2337/dc24-2147","DOIUrl":"10.2337/dc24-2147","url":null,"abstract":"<p><strong>Objective: </strong>We investigated the association between historic redlining and risk of gestational diabetes mellitus (GDM) and whether this relationship is mediated by maternal obesity and area-level deprivation.</p><p><strong>Research design and methods: </strong>This retrospective study included 86,834 singleton pregnancies from Kaiser Permanente Southern California's health records (2008-2018). Redlining was assessed using digitized Home Owners' Loan Corporation (HOLC) maps, with patients' residential addresses geocoded and assigned HOLC grades (A, B, C, or D) based on their geographic location within HOLC-graded zones. For GDM case patients, exposure was assigned based on address at diagnosis date; for noncase patients, it was assigned based on address during the 24th to 28th gestational week. Health records were combined with area deprivation index (ADI) from 2011 to 2015 census data. Mixed-effect logistic regression models assessed associations between redlining and GDM, with mediation by BMI and ADI evaluated using inverse odds ratio weighting. Models were adjusted for maternal age, education, race and ethnicity, neighborhood-level income, and smoking status.</p><p><strong>Results: </strong>Among the 10,134 (11.67%) GDM case patients, we found increased risk of GDM in B (\"still desirable,\" adjusted odds ratio [aOR] 1.20, 95% CI 0.99-1.44), C-graded (\"definitely declining,\" aOR 1.22, 95% CI 1.02-1.47), and D-graded (\"hazardous,\" i.e., redlined, aOR 1.30, 95% CI 1.08-1.57) neighborhoods compared with the \"best\"-graded zone. Prepregnancy BMI and ADI mediated 44.2% and 64.5% of the increased GDM risk among mothers in redlined areas.</p><p><strong>Conclusions: </strong>Historic redlining is associated with an increased risk of GDM, mediated by maternal obesity and neighborhood deprivation. Future research is needed to explore the complex pathways linking redlining to pregnancy outcomes.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"711-718"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12034896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.","authors":"John B Buse, Steven E Kahn, Vanita R Aroda, Richard J Auchus, Timothy Bailey, Irina Bancos, Robert S Busch, Elena A Christofides, Ralph A DeFronzo, Bradley Eilerman, James W Findling, Vivian Fonseca, Oksana Hamidi, Yehuda Handelsman, Harold J Miller, Jonathan G Ownby, John C Parker, Athena Philis-Tsimikas, Richard Pratley, Julio Rosenstock, Michael H Shanik, Lance L Sloan, Guillermo Umpierrez, Iulia Cristina Tudor, Tina K Schlafly, Daniel Einhorn","doi":"10.2337/dc24-2841","DOIUrl":"https://doi.org/10.2337/dc24-2841","url":null,"abstract":"<p><strong>Objective: </strong>Despite the use of multiple glucose-lowering medications, glycemic targets are not met in a significant fraction of people with type 2 diabetes. In this prospective, observational study we assessed the prevalence of hypercortisolism, a potential contributing factor to inadequate glucose control.</p><p><strong>Research design and methods: </strong>Individuals with type 2 diabetes and HbA1c 7.5%-11.5% (58-102 mmol/mol) on two or more glucose-lowering medications with or without micro-/macrovascular complications or taking multiple blood pressure-lowering medications were screened with a 1-mg dexamethasone suppression test. Common causes of false-positive DSTs were excluded. The primary end point was the prevalence of hypercortisolism, defined as post-DST cortisol >1.8 μg/dL (50 nmol/L). Characteristics associated with hypercortisolism were assessed with multiple logistic regression. The percentage and characteristics of participants with hypercortisolism and adrenal imaging abnormalities were also assessed.</p><p><strong>Results: </strong>Post-DST cortisol was unsuppressed in 252 of 1,057 participants (prevalence 23.8%; 95% CI 21.3, 26.5). Hypercortisolism prevalence was 33.3% among participants with cardiac disorders and 36.6% among those taking three or more blood pressure-lowering medications. Adrenal imaging abnormalities were reported in 34.7% of participants with hypercortisolism. Use of sodium-glucose cotransporter 2 inhibitors (odds ratio 1.558), maximum-dose glucagon-like peptide 1 receptor agonists (1.544), tirzepatide (1.981), or a higher number of blood pressure-lowering medications (1.390); older age (1.316); BMI <30 kg/m2 (1.639); non-Latino/Hispanic ethnicity (3.718); and use of fibrates (2.676) or analgesics (1.457) were associated with higher prevalence (all P < 0.03).</p><p><strong>Conclusions: </strong>Hypercortisolism was associated with hyperglycemia in approximately one-quarter of individuals with inadequately controlled type 2 diabetes despite multiple medications.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2025. Diabetes Care 2025;48(Suppl. 1):S86-S127.","authors":"","doi":"10.2337/dc25-er04a","DOIUrl":"10.2337/dc25-er04a","url":null,"abstract":"","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"665"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}